Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma: early-phase trial registry
88 of 330 indexed Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #21 of 28,707 conditions by registered trial count.
330 US clinical trials · 88 currently recruiting · #21 of 28,707 conditions by registered trial count
Lymphoma: 330 US clinical trials tracked, 88 recruiting.
Lymphoma is the subject of 330 registered US clinical trials on ClinicalTrials.gov, 88 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 229 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition lymphoma
OPEN 88 | RECR 27% | LATE 25 | EARLY 229 | RANK #21 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Age-related Macular Degeneration (27% recruiting · 75 trials)
Lymphoma lists 88 open slots (27% of 330 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma is recruiting below its size-band peers.
88 of 330 indexed trials (26.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 330 trials (10.3%). 116 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 300 trials that report a genuine target (sentinel values excluded). 213 of those (71%) plan for fewer than 100 participants.
-
Lymphoma research is mostly interventional.
299 interventional and 31 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
330 total, page 7 of 7
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
OHSU Knight Cancer Institute
NCT00074191
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NYU Langone Health
NCT00004002
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
Boston Medical Center
NCT00006340
Depsipeptide in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
NCT00019318
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
NCT00002502
Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
AIDS Malignancy Consortium
NCT00006264
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
NCT00019656
UCN-01 in Treating Patients With Advanced Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00003289
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
NCT00004232
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
NCT00064311
Immunotoxin in Treating Patients With Leukemia or Lymphoma
National Cancer Institute (NCI)
NCT00002765
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00005804
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT00030849
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University School of Medicine
NCT00003107
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
NCT00070447
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia
University of Vermont
NCT00005579
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Temple University
NCT00002522
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
NCT00004112
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00006098
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
NCT00006362
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT00014482
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Vion Pharmaceuticals
NCT00049699
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00003395
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
NCT00006083
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
NCT00059904
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
National Cancer Institute (NCI)
NCT00003368
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Mayo Clinic
NCT00004260
Monoclonal Antibody Therapy in Treating Patients With Leukemia
National Cancer Institute (NCI)
NCT00019227
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00006042
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
NCT00004197
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 110 |
| Phase 3 | 22 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma page
330 registered trials, 88 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 88 Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma condition card totals 330 registered trials; most-linked intervention cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.